Here, the abilities of RA, Lut, and RS to bind effectively with the twelve protein targets (α-amylase, α-glucosidase, pancreatic lipase, SGLT-2, AMPK, glucokinase, aldose reductase, acetylcholinesterase, acetylcholine M2 receptor, GLP-1R, DPP-IV, and PPAR-γ) could be pivotal in the treatment of T2DM, in addition to the link capabilities of the metabolites to interact more strongly than the standard drugs with the individual receptors. The gene discussed is GLP1R; the disease is type 2 diabetes mellitus.